TY - JOUR
T1 - Long-term safety of risperidone
AU - Davidson, M.
N1 - Funding Information:
Supported by the Health Research Board.
PY - 2001
Y1 - 2001
N2 - In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day). During 12-month, open-label extensions to these studies, the incidence of de novo tardive dyskinesia was very low. No clinically significant adverse events, changes in vital signs, or laboratory signs were observed. In summary, the safety and tolerability of risperidone in treating elderly dementia sufferers has been favorable in several clinical trials.
AB - In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day). During 12-month, open-label extensions to these studies, the incidence of de novo tardive dyskinesia was very low. No clinically significant adverse events, changes in vital signs, or laboratory signs were observed. In summary, the safety and tolerability of risperidone in treating elderly dementia sufferers has been favorable in several clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0034791415&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11584985
AN - SCOPUS:0034791415
SN - 0160-6689
VL - 62
SP - 26
EP - 28
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - SUPPL. 22
ER -